Two chemoattractants for retinal pigment epithelial (RPE) cells, fibronectin (FN) and platelet-derived growth factor (PDGF) were found to enhance protein carboxymethylation mediated by S-adenosyl-L-methionine in RPE cells measured by [3H]methanol hydrolyzed from TCA precipitable protein methyl esters labelled with [3H]methionine. The effect was rapid, peaking at 2 min when [3H]methanol production was enhanced 120% by FN and 150% by PDGF. Erythro-9-(2-hydroxy-3-nonyl) adenine (EHNA; 10μM), adeno-sine (100 μM), and L-homocysteine thiolactone (100 μM) inhibited FN-induced carboxymethylation by 60%, and PDGF-induced carboxymethylation by 59%. In modified Boyden chamber assays, the combination of EHNA (10 μM), adenosine (100 μM), and L-homocysteine thiolactone (100 μM) markedly inhibited FN-induced chemotaxis by 88% and PDGF-induced chemotaxis by 93%). Migration of RPE cells has been implicated in the pathogenesis of proliferative vitreoretinopathy (PVR). Inhibition of protein carboxymethylation may provide a new target in the development of pharmacologic therapy for PVR.

Keywords:
Retinal pigment epithelium, Chemotaxis, Carboxymethylation, Proliferative vitreoretinopathy
This content is only available via PDF.
© 1988 S. Karger AG, Basel
1988
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.